Literature DB >> 11403533

Histamine receptor antagonists, proton pump inhibitors and their combination in the treatment of gastro-oesophageal reflux disease.

P O Katz1, R Tutuian.   

Abstract

The medical treatment of gastro-oesophageal reflux disease is accomplished with the appropriate use of anti-secretory therapy, principally H(2)-receptor antagonists and proton pump inhibitors. In fact, there is a direct correlation between the length of time, in terms of the number of hours per day that the intragastric pH is above 4, and the healing of the oesophagitis. Nowadays, H(2)-receptor antagonists are of limited use as primary treatment, being inferior to proton pump inhibitors in both healing and symptom relief. Although the majority of patients can be effectively managed with carefully titrated doses of proton pump inhibitors, a small number will continue to show difficulty in the management of their disease, principally because of inadequate nocturnal acid control. These patients may benefit from a combination of proton pump inhibitors twice daily with an H(2)-receptor antagonist at bedtime. This article reviews the use of H(2)-antagonists, proton pump inhibitors and their combination in the management of the patient with gastro-oesophageal reflux disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11403533     DOI: 10.1053/bega.2001.0185

Source DB:  PubMed          Journal:  Best Pract Res Clin Gastroenterol        ISSN: 1521-6918            Impact factor:   3.043


  5 in total

1.  Inadequate use of acid-suppressive therapy in hospitalized patients and its implications for general practice.

Authors:  Raffaella Scagliarini; Elena Magnani; Antonino Praticò; Renato Bocchini; Paola Sambo; Paolo Pazzi
Journal:  Dig Dis Sci       Date:  2005-12       Impact factor: 3.199

2.  The Current Use of Proton-Pump Inhibitor Therapy in Clinical GI Practice.

Authors:  Philip O Katz
Journal:  Gastroenterol Hepatol (N Y)       Date:  2006-12

3.  Pharmacokinetics, absorption, and excretion of radiolabeled revexepride: a Phase I clinical trial using a microtracer and accelerator mass spectrometry-based approach.

Authors:  Stephen Flach; Marie Croft; Jie Ding; Ron Budhram; Todd Pankratz; Mike Pennick; Graeme Scarfe; Steven Troy; Jay Getsy
Journal:  Drug Des Devel Ther       Date:  2016-09-27       Impact factor: 4.162

Review 4.  Issues and controversies in esophageal inlet patch.

Authors:  Adriana Ciocalteu; Petrica Popa; Mircea Ionescu; Dan Ionut Gheonea
Journal:  World J Gastroenterol       Date:  2019-08-14       Impact factor: 5.742

5.  Evaluation of rational nonsteroidal anti-inflammatory drugs and gastro-protective agents use; association rule data mining using outpatient prescription patterns.

Authors:  Oraluck Pattanaprateep; Mark McEvoy; John Attia; Ammarin Thakkinstian
Journal:  BMC Med Inform Decis Mak       Date:  2017-07-04       Impact factor: 2.796

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.